Synaptojanin 2 is a druggable mediator of metastasis and the gene is overexpressed and amplified in breast cancer

Nir Ben-Chetrit; David Chetrit; Roslin Russell; Cindy Körner; Maicol Mancini; Ali Abdul-Hai; Tomer Itkin; Silvia Carvalho; Hadas Cohen-Dvashi; Wolfgang J. Koestler; Kirti Shukla; Moshit Lindzen; Merav Kedmi; Mattia Lauriola; Ziv Shulman; Haim Barr; Dalia Seger; Daniela A. Ferraro; Fresia Pareja; Hava Gil-Henn; Tsvee Lapidot; Ronen Alon; Ferna Milanezi; Marc Symons; Rotem Ben-Hamo; Sol Efroni; Ferno Schmitt; Stefan Wiemann; Carlos Caldas; Marcelo Ehrlich; Yosef Yarden

doi:10.1126/scisignal.2005537

Synaptojanin 2 is a druggable mediator of metastasis and the gene is overexpressed and amplified in breast cancer

Nir Ben-Chetrit, David Chetrit, Roslin Russell, Cindy Körner, Maicol Mancini, Ali Abdul-Hai, Tomer Itkin, Silvia Carvalho, Hadas Cohen-Dvashi, Wolfgang J. Koestler, Kirti Shukla, Moshit Lindzen, Merav Kedmi, Mattia Lauriola, Ziv Shulman, Haim Barr, Dalia Seger, Daniela A. Ferraro, Fresia Pareja, Hava Gil-HennTsvee Lapidot, Ronen Alon, Ferna Milanezi, Marc Symons, Rotem Ben-Hamo, Sol Efroni, Ferno Schmitt, Stefan Wiemann, Carlos Caldas, Marcelo Ehrlich, Yosef Yarden^*

^*Corresponding author for this work

Department of Cell Research and Immunology

Research output: Contribution to journal › Article › peer-review

53 Scopus citations

Abstract

Amplified HER2, which encodes a member of the epidermal growth factor receptor (EGFR) family, is a target of effective therapies against breast cancer. In search for similarly targetable genomic aberrations, we identified copy number gains in SYNJ2, which encodes the 5′-inositol lipid phosphatase synaptojanin 2, as well as overexpression in a small fraction of human breast tumors. Copy gain and overexpression correlated with shorter patient survival and a low abundance of the tumor suppressor microRNA miR-31. SYNJ2 promoted cell migration and invasion in culture and lung metastasis of breast tumor xenografts in mice. Knocking down SYNJ2 impaired the endocytic recycling of EGFR and the formation of cellular lamellipodia and invadopodia. Screening compound libraries identified SYNJ2-specific inhibitors that prevented cell migration but did not affect the related neural protein SYNJ1, suggesting that SYNJ2 is a potentially druggable target to block cancer cell migration.

Original language	English
Article number	ra7
Journal	Science Signaling
Volume	8
Issue number	360
DOIs	https://doi.org/10.1126/scisignal.2005537
State	Published - 20 Jan 2015

Funding

Funders	Funder number
Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
European Research Council
Israel Cancer Research Fund
National Cancer Institute

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1126/scisignal.2005537

Cite this

Ben-Chetrit, N., Chetrit, D., Russell, R., Körner, C., Mancini, M., Abdul-Hai, A., Itkin, T., Carvalho, S., Cohen-Dvashi, H., Koestler, W. J., Shukla, K., Lindzen, M., Kedmi, M., Lauriola, M., Shulman, Z., Barr, H., Seger, D., Ferraro, D. A., Pareja, F., ... Yarden, Y. (2015). Synaptojanin 2 is a druggable mediator of metastasis and the gene is overexpressed and amplified in breast cancer. Science Signaling, 8(360), Article ra7. https://doi.org/10.1126/scisignal.2005537

@article{ec60c41575974936bfa3dd696261461c,

title = "Synaptojanin 2 is a druggable mediator of metastasis and the gene is overexpressed and amplified in breast cancer",

abstract = "Amplified HER2, which encodes a member of the epidermal growth factor receptor (EGFR) family, is a target of effective therapies against breast cancer. In search for similarly targetable genomic aberrations, we identified copy number gains in SYNJ2, which encodes the 5′-inositol lipid phosphatase synaptojanin 2, as well as overexpression in a small fraction of human breast tumors. Copy gain and overexpression correlated with shorter patient survival and a low abundance of the tumor suppressor microRNA miR-31. SYNJ2 promoted cell migration and invasion in culture and lung metastasis of breast tumor xenografts in mice. Knocking down SYNJ2 impaired the endocytic recycling of EGFR and the formation of cellular lamellipodia and invadopodia. Screening compound libraries identified SYNJ2-specific inhibitors that prevented cell migration but did not affect the related neural protein SYNJ1, suggesting that SYNJ2 is a potentially druggable target to block cancer cell migration.",

author = "Nir Ben-Chetrit and David Chetrit and Roslin Russell and Cindy K{\"o}rner and Maicol Mancini and Ali Abdul-Hai and Tomer Itkin and Silvia Carvalho and Hadas Cohen-Dvashi and Koestler, {Wolfgang J.} and Kirti Shukla and Moshit Lindzen and Merav Kedmi and Mattia Lauriola and Ziv Shulman and Haim Barr and Dalia Seger and Ferraro, {Daniela A.} and Fresia Pareja and Hava Gil-Henn and Tsvee Lapidot and Ronen Alon and Ferna Milanezi and Marc Symons and Rotem Ben-Hamo and Sol Efroni and Ferno Schmitt and Stefan Wiemann and Carlos Caldas and Marcelo Ehrlich and Yosef Yarden",

year = "2015",

month = jan,

day = "20",

doi = "10.1126/scisignal.2005537",

language = "אנגלית",

volume = "8",

journal = "Science Signaling",

issn = "1945-0877",

publisher = "American Association for the Advancement of Science",

number = "360",

}

Ben-Chetrit, N, Chetrit, D, Russell, R, Körner, C, Mancini, M, Abdul-Hai, A, Itkin, T, Carvalho, S, Cohen-Dvashi, H, Koestler, WJ, Shukla, K, Lindzen, M, Kedmi, M, Lauriola, M, Shulman, Z, Barr, H, Seger, D, Ferraro, DA, Pareja, F, Gil-Henn, H, Lapidot, T, Alon, R, Milanezi, F, Symons, M, Ben-Hamo, R, Efroni, S, Schmitt, F, Wiemann, S, Caldas, C, Ehrlich, M & Yarden, Y 2015, 'Synaptojanin 2 is a druggable mediator of metastasis and the gene is overexpressed and amplified in breast cancer', Science Signaling, vol. 8, no. 360, ra7. https://doi.org/10.1126/scisignal.2005537

TY - JOUR

T1 - Synaptojanin 2 is a druggable mediator of metastasis and the gene is overexpressed and amplified in breast cancer

AU - Ben-Chetrit, Nir

AU - Chetrit, David

AU - Russell, Roslin

AU - Körner, Cindy

AU - Mancini, Maicol

AU - Abdul-Hai, Ali

AU - Itkin, Tomer

AU - Carvalho, Silvia

AU - Cohen-Dvashi, Hadas

AU - Koestler, Wolfgang J.

AU - Shukla, Kirti

AU - Lindzen, Moshit

AU - Kedmi, Merav

AU - Lauriola, Mattia

AU - Shulman, Ziv

AU - Barr, Haim

AU - Seger, Dalia

AU - Ferraro, Daniela A.

AU - Pareja, Fresia

AU - Gil-Henn, Hava

AU - Lapidot, Tsvee

AU - Alon, Ronen

AU - Milanezi, Ferna

AU - Symons, Marc

AU - Ben-Hamo, Rotem

AU - Efroni, Sol

AU - Schmitt, Ferno

AU - Wiemann, Stefan

AU - Caldas, Carlos

AU - Ehrlich, Marcelo

AU - Yarden, Yosef

PY - 2015/1/20

Y1 - 2015/1/20

N2 - Amplified HER2, which encodes a member of the epidermal growth factor receptor (EGFR) family, is a target of effective therapies against breast cancer. In search for similarly targetable genomic aberrations, we identified copy number gains in SYNJ2, which encodes the 5′-inositol lipid phosphatase synaptojanin 2, as well as overexpression in a small fraction of human breast tumors. Copy gain and overexpression correlated with shorter patient survival and a low abundance of the tumor suppressor microRNA miR-31. SYNJ2 promoted cell migration and invasion in culture and lung metastasis of breast tumor xenografts in mice. Knocking down SYNJ2 impaired the endocytic recycling of EGFR and the formation of cellular lamellipodia and invadopodia. Screening compound libraries identified SYNJ2-specific inhibitors that prevented cell migration but did not affect the related neural protein SYNJ1, suggesting that SYNJ2 is a potentially druggable target to block cancer cell migration.

AB - Amplified HER2, which encodes a member of the epidermal growth factor receptor (EGFR) family, is a target of effective therapies against breast cancer. In search for similarly targetable genomic aberrations, we identified copy number gains in SYNJ2, which encodes the 5′-inositol lipid phosphatase synaptojanin 2, as well as overexpression in a small fraction of human breast tumors. Copy gain and overexpression correlated with shorter patient survival and a low abundance of the tumor suppressor microRNA miR-31. SYNJ2 promoted cell migration and invasion in culture and lung metastasis of breast tumor xenografts in mice. Knocking down SYNJ2 impaired the endocytic recycling of EGFR and the formation of cellular lamellipodia and invadopodia. Screening compound libraries identified SYNJ2-specific inhibitors that prevented cell migration but did not affect the related neural protein SYNJ1, suggesting that SYNJ2 is a potentially druggable target to block cancer cell migration.

UR - http://www.scopus.com/inward/record.url?scp=84921797782&partnerID=8YFLogxK

U2 - 10.1126/scisignal.2005537

DO - 10.1126/scisignal.2005537

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 25605973

AN - SCOPUS:84921797782

SN - 1945-0877

VL - 8

JO - Science Signaling

JF - Science Signaling

IS - 360

M1 - ra7

ER -

Synaptojanin 2 is a druggable mediator of metastasis and the gene is overexpressed and amplified in breast cancer

Abstract

Funding

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this